Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Benlysta 400 mg powder for concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
belimumab
Company:  
GlaxoSmithKline UK See contact details
ATC code: 
L04AA26
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Live Chat HCP Med Info
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 03 Apr 2024

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF
GlaxoSmithKline UK
Company image
Address
79 New Oxford Street, London, WC1A 1DG, UK
Telephone
0800 221 441
Medical Information e-mail
[email protected]
E-mail
[email protected]
Adverse event reporting email
[email protected]